# Decibel Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/decibel-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.decibeltx.com
- Total disclosed funding: $188M
- Latest round: Series D (Nov 9, 2020)
- Investors on record: 17

## About

Based in Massachusetts, US, and was founded in 2015, Decibel Therapeutics, Inc. is a biotechnology company and as of 2021 it has 11 team members, including Senior Director, Product and Market Strategy Erik Larsen, and has 2 board members and advisors, including Anthony Philippakis.

In November 2017, Decibel had a strategic partnership with Regeneron Pharmaceuticals, and that gives access to world-leading capabilities in genetics research, drug discovery, and antibody development and manufacturing. In November 2020, Decibel Therapeutics, Inc. raised USD 82.2 million in series D funding led by new investor OrbiMed Advisors, with participation from other new investors BlackRock, Casdin Capital, Janus Capital Group, Samsara BioCapital, and Surveyor Capital. Also, In 2021, Decibel Therapeutics became a publicly listed company trading on the Nasdaq under the ticker symbol DBTX. 

Decibel Therapeutics, Inc. leverages single-cell genomics capabilities through its research, discovery, and drug development platform. The company provides its patients with treatments and medicines for hearing and balance disabilities. Decibel Therapeutics, Inc. is planning to be listed on the Nasdaq under the symbol DBTX.

## Funding rounds

- Series D, Nov 9, 2020, $55M — OrbiMed Advisors, SR One, Third Rock Ventures, GV, Janus Henderson Investors, Surveyor Capital, BlackRock, Foresite Capital, Casdin Capital, S-Cubed Capital, Sobrato Family Holdings, Samsara BioCapital
- Series C, May 24, 2018, $55M — Schroders Capital, Bessemer Trust, SR One, Third Rock Ventures, GV, Foresite Capital, S-Cubed Capital, The Longevity Fund, Regeneron Pharmaceuticals, Inc.
- Series B, Nov 14, 2017, $25M — Third Rock Ventures, GV
- Series A, Jan 6, 2017, $45M — Third Rock Ventures
- Series A, Oct 13, 2015, $8M — SR One, Third Rock Ventures, GlaxoSmithKline

## Investors

- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series C, Series D
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B, Series C, Series D
- GlaxoSmithKline — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C, Series D
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series C
- Bessemer Trust — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C, Series D
- S-Cubed Capital — Series C, Series D
- The Longevity Fund (https://capitalatlas.ai/funds/the-longevity-fund) — Series C
- Regeneron Pharmaceuticals, Inc. — Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D
- Janus Henderson Investors — Series D
- Surveyor Capital — Series D
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series D
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series D
- Sobrato Family Holdings — Series D
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series D